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Introduction and aim: Percutaneous mitral valvuloplasty (PMV) is an effective treatment option
for mitral stenosis (MS), but its success is assessed on the basis of clinical and echocardio-
graphic outcomes in studies with relatively short follow-up. We aimed to characterize a cohort
of patients undergoing PMV with long-term follow-up and to determine independent predictors
of post-PMV mitral re-intervention and event-free survival.
Methods: We studied 91 consecutive patients with MS who underwent PMV with a median
clinical follow-up duration of 99 months. Two endpoints were considered: post-PMV mitral
re-intervention (PMV or mitral surgery) and a composite clinical events endpoint including car-
diovascular death, mitral valve re-intervention and hospital admission due to decompensated
heart failure. We compared patients who required post-PMV mitral re-intervention with those
who did not during follow-up.
Results: The study population included 83.5% females and mean age was 48.9± 13.9 years.
The 1-, 3-, 5-, 7- and 9-year rates of clinical event-free survival were 93.0± 2.8%, 86.0± 3.9%,
81.0± 4.4%, 70.6± 5.6%, and 68.4± 5.8%, respectively. The 1-, 3-, 5-, 7- and 9-year rates of
mitral re-intervention-free survival were 98.8± 1.2%, 97.5± 1.7%, 92.1± 3.1%, 85.5± 4.5%, and
85.5± 4.5%, respectively. The median time to mitral re-intervention was 6.2 years. Patients who
required mitral re-intervention during follow-up were younger (43.3 vs. 51.2 years, p=0.04)
and had higher pre- and post-PMV mitral gradient (14.9 vs. 11.5mmHg, p=0.02 and 6.4 vs.
2.1mmHg, p<0.001) and higher post-PMV mean pulmonary artery pressure (mPAP) (30.0 vs.
23.2mmHg, p=0.01). In a Cox proportional hazards model, mPAP ≥25mmHg was the sole pre-
dictor of both mitral re-intervention (HR 5.639 [1.246--25.528], p=0.025) and clinical events
(HR 3.622 [1.070--12.260], p=0.039).
Conclusion: In our population, immediate post-PMV mPAP was the sole predictor of post-PMV
mitral intervention. These ﬁndings may help identify patients in need of closer post-PMV
follow-up.
© 2011 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L. All rights
reserved.
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A pressão média na artéria pulmonar após a valvuloplastia mitral percutânea é um
preditor de mau prognóstico a longo prazo
Resumo
Introduc¸ão e objetivos: A valvuloplastia mitral percutânea (PMV) é uma opc¸ão eﬁcaz para o
tratamento da estenose mitral. Contudo, os resultados deste procedimento são baseados em
estudos clínicos e ecocardiográﬁcos com tempos de seguimento relativamente curtos. Os obje-
tivos deste estudo são caracterizar uma populac¸ão de doentes submetidos a PMV, realizar um
seguimento clínico de longa durac¸ão e determinar os preditores independentes de reintervenc¸ão
mitral após PMV e de sobrevida livre de eventos.
Métodos: Foi estudada uma populac¸ão de 91 doentes com estenose mitral tratada por
PMV e realizou-se um seguimento clínico com a durac¸ão média de 99 meses. Foram
pré-deﬁnidos dois endpoints: reintervenc¸ão mitral pós-PMV (PMV ou cirurgia mitral) e
um endpoint clínico combinado que incluiu morte de causa cardiovascular, reintervenc¸ão
mitral e internamento hospitalar por insuﬁciência cardíaca descompensada. Foi real-
izado um estudo comparativo entre os doentes que necessitaram de reintervenc¸ão mitral
após PMV e os que não foram reintervencionados durante o tempo de seguimento
clínico.
Resultados: A populac¸ão estudada incluiu 83,5% de mulheres e a idade média foi de 48,9 ±
13,9 anos. As taxas de sobrevida livre de eventos aos 1, 3, 5, 7 e 9 anos foram de 93,0 ± 2,8%;
86,0 ± 3,9%; 81,0 ± 4,4%; 70,6 ± 5,6% e 68,4 ± 5,8%, respetivamente. As taxas de sobrevida
sem reintervenc¸ão mitral aos 1, 3, 5, 7 e 9 anos foram de 98,8 ± 1,2%; 97,5 ± 1,7%; 92,1 ±
3,1%; 85,5 ± 4,5% e 85,5 ± 4,5%, respectivamente. O tempo mediano até à reintervenc¸ão mitral
foi de 6,2 anos. Os doentes que necessitaram de reintervenc¸ão mitral durante o seguimento
clínico eram mais novos (43,3 vs. 51,2 anos, p = 0,04), tinham gradientes transmitrais pré
e pós-PMV mais elevados (14,9 vs. 11,5mmHg, p = 0,02 e 6,4 vs. 2,1mmHg, p < 0,001) e
uma pressão média na artéria pulmonar (mPAP) pós-PMV mais elevada (30,0 vs. 23,2mmHg,
p = 0,01). No modelo de regressão logística de Cox a mPAP ≥ 25mmHg foi o único preditor de
reintervenc¸ão mitral (HR 5,639 [1,2-25,5], p = 0,025) e de eventos clínicos (HR 3,6 [1,1-12,3],
p = 0,039).
Conclusão: Na populac¸ão estudada, a mPAP medida imediatamente após a valvuloplastia
mitral foi o único preditor de reintervenc¸ão mitral. Os resultados deste estudo podem con-
tribuir para a identiﬁcac¸ão dos doentes que beneﬁciam de um seguimento pós-PMV mais
frequente.



































stored in an electronic database. Demographic, clinicalntroduction
ercutaneous mitral valvuloplasty (PMV) is an effective
reatment option for hemodynamically signiﬁcant mitral
tenosis (MS) and has become the procedure of choice in
atients with suitable valve anatomy.1--5 However, the pro-
edural success of PMV is assessed on the basis of clinical and
chocardiographic outcomes in studies with relatively short
ollow-up (<5 years).2--4,6,7 Restenosis is the main mechanism
f deterioration following an initially successful PMV3 and
ts development is time-dependent,3,8 reﬂecting the wide
ange of reported restenosis incidence (4--39%) according
o different follow-up durations.2,3,9--11 Cardiac surgery may
till be required for patients with post-procedural restenosis
f the mitral oriﬁce or increasing severity of mitral regur-
itation (MR).6 In this study, we sought to characterize a
ohort of patients undergoing PMV at a single institution
nd to perform a long-term clinical follow-up to assess






his single-center study included 91 consecutive patients
ith MS who underwent PMV between March 1992 and June
010 in our institution. The indications for PMV were as
ollows: symptomatic patients with moderate or severe MS
ith favorable valve morphology; asymptomatic patients
ith moderate to severe MS and pulmonary hypertension
pulmonary artery systolic pressure >50mmHg at rest) with
avorable valve morphology; and symptomatic patients with
oderate or severe MS with unfavorable valve morphology
ut not candidates or at high risk for surgery. Determination
f favorable valve morphology was based on echocardio-
raphic evaluation. Data was collected prospectively andnd laboratory variables included age, gender, New York
eart Association (NYHA) functional class at presentation,


















































oMean pulmonary arterial pressure after percutaneous mitral
and echocardiographic score. Procedure-related variables
included interventional technique, effective balloon dilat-
ing area normalized by body surface area, and pre- and
post-PMV hemodynamic parameters (ventricular, atrial and
pulmonary artery pressures, mean mitral gradient [MG]),
cardiac output and calculated mitral valve area [MVA]. Pro-
cedural success was deﬁned as MVA≥1.5 cm2 and MR≤2/4,
as used by Song et al.12 Written informed consent was
obtained from all patients prior to PMV.
Echocardiographic evaluation
Comprehensive two-dimensional and color Doppler transtho-
racic echocardiogram was performed before PMV. The
morphologic features of the mitral valve were categorized
using the Wilkins echo score13 and the total echocardio-
graphic score was obtained by adding the scores for leaﬂet
mobility, thickness, calciﬁcation, and subvalvular lesions.
MVA was measured by direct planimetry in parasternal
short-axis view, and continuous wave Doppler was used
to calculate peak pressure gradient of tricuspid regurgita-
tion. Mitral and tricuspid regurgitation were graded from
0 to 4+, depending on the spatial extent of the color ﬂow
jet area expressed as a percentage of the left or right
atrial area. Patients were screened for left atrial thrombus
with a two-dimensional transesophageal echocardiogram
in the 24 h preceding the procedure. If thrombus was
detected, the patient was not a candidate for PMV.
Transthoracic echocardiographic measurement of MVA and
quantiﬁcation of MR were repeated one day after PMV.
Percutaneous mitral valvuloplasty
After cardiac catheterization conﬁrmed severe MS with-
out signiﬁcant MR, experienced physicians performed PMV
using a percutaneous transseptal antegrade approach and
the Inoue balloon technique, while monitoring conventional
hemodynamic parameters. Balloon size was chosen to obtain
an effective balloon dilatation area/body surface area of
approximately 4 cm2/m2, and one-step dilatation was per-
formed. Maximum balloon size was determined by the
following formula: patient’s height (cm)/10 + 10. MVA was
calculated using the Gorlin formula.14 Left ventriculography
was performed to assess the presence and severity of MR,
and Sellers’ classiﬁcation was applied.15
Clinical follow-up
Clinical follow-up with a median duration of 99 months
(interquartile range [IQR] 63--176) was performed for 85/91
(93.4%) patients. Clinical data was collected during patients’
visits to the outpatient clinic or by telephone inter-
view. When required, primary care physicians and referring
cardiologists were contacted and medical records were
reviewed to obtain additional information. Surgical notes
were obtained on all patients who underwent surgery after
PMV. Two predeﬁned study endpoints were assessed: (1)
post-PMV mitral re-intervention (PMV or mitral surgery) and
(2) a composite clinical events endpoint including cardio-





dmission due to decompensated heart failure. The popu-
ation was divided into two groups according to need for
ost-PMV mitral re-intervention. Patients who underwent
itral surgery immediately after PMV due to iatrogenic
evere MR were excluded from the analysis (n=3).
tatistical analysis
ontinuous variables were expressed as mean± SD. Median
nd IQR were used if the distribution was not normal,
ssessed by the Kolmogorov--Smirnov test. The Student’s
npaired t-test for normal variables and the Mann--Whitney
test for non-normal variables were used for compar-
sons between groups. The paired-sample t-test was used
o compare pre- and post-PMV variables. Categorical vari-
bles were presented as percentages, and were compared
sing the chi-square or Fisher’s exact test. All variables
ere tested independently in a univariate logistic regression
odel, and those that achieved a signiﬁcance level of p<0.10
ere incorporated in a Cox proportional hazards regression
odel for both predeﬁned endpoints. Receiver operating
urves were calculated to determine the best cut-off values.
ariables associated with a p value <0.05 were retained in
he ﬁnal model. Kaplan--Meier estimates were used to deter-
ine event-free survival. Comparison between groups was
erformed using the log rank test. Statistical analyses were
erformed with SPSS (13.0 for Windows, SPSS Inc., Chicago,
L, USA).
esults
he study population included 91 consecutive patients.
aseline clinical, echocardiographic and hemodynamic
haracteristics were compared in patients who required
ost-PMV mitral re-intervention and those that did not are
ummarized in Tables 1 and 2. All patients had an echo score
nder 8, reﬂecting the selected nature of this population.
Procedural success was achieved in 75 of 91 (82.4%)
atients, using the above-mentioned deﬁnition. The 16 inad-
quate immediate results were related to suboptimal valve
pening (valve area <1.5 cm2) in 12 cases (75%) and severe
R (grade≥ 3) in four cases (25%).
Mean pre-PMV MVA and MG were 1.0±0.3 cm2 and
2.3±5.2mmHg and improved to 2.3±0.4 cm2 and 3.0±
.8mmHg after PMV, respectively (p<0.001 for both). The
edian time to mitral re-intervention was 6.2 (3.3--10.8)
ears.
The 1-, 3-, 5-, 7- and 9-year rates of post-PMV mitral
e-intervention-free survival were 98.8±1.2%, 97.5±1.7%,
2.1±3.1%, 85.5±4.5%, and 85.5±4.5%, respectively
Figure 1). Regarding the second endpoint, the 1-, 3-,
-, 7- and 9-year rates of clinical event-free survival
ere 93.0±2.8%, 86.0±3.9%, 81.0±4.4%, 70.6±5.6%, and
8.4±5.8%, respectively.
During follow-up, nine patients died, four due to car-
iovascular causes. Fifteen patients underwent mitral valve
pen heart surgery (eight underwent mitral valve replace-
ent with a mechanic prosthesis and seven mitral valve
epair) and four underwent repeat PMV; one patient under-
ent both procedures. In addition, eight hospital admissions
ue to decompensated heart failure were recorded. No
22 E. Jorge et al.
Table 1 Baseline clinical and echocardiographic characteristics of patients who did and did not require post-PMV mitral re-
intervention.





Age (years) 48.9±13.9 51.2±13.8 43.3±12.8 0.040
Female gender 84.1% 83.6% 86.7% 0.767
Body mass index (kg/m2) 25.2±3.5 25.5±3.4 23.6±2.7 0.050
Atrial ﬁbrillation 29.6% 31.8% 20.0% 0.366
Echo score 6 (5--7) 6 (5--7) 6 (5--6) 0.360a
Prior commissurotomy 3.7% 3.0% 6.7% 0.492
MVA (cm2) 1.1±0.2 1.1±0.2 1.0±0.2 0.370
NYHA III/IV 53.2% 56.3% 38.5% 0.241
MVA: mitral valve area; NYHA: New York Heart Association; PMV: percutaneous mitral valvuloplasty. Results are expressed as mean± SD
or median (interquartile range), as appropriate.
a Mann--Whitney U test.
Table 2 Hemodynamic ﬁndings in patients who did and did not require post-PMV mitral re-intervention.






Pre-PMV 1.0± 0.3 1.0± 0.3 0.9± 0.3 0.160
Post-PMV 2.3± 0.4 2.3± 0.5 2.3± 0.3 0.790
Mean MG
Pre-PMV 12.3± 5.2 11.5± 5.0 14.9± 5.1 0.020
Post-PMV 3.0± 3.8 2.1± 2.2 6.4± 6.8 <0.001
RA pressure
Pre-PMV 7.8± 4.5 7.6± 4.8 8.9± 3.4 0.380
Post-PMV 9.0± 4.7 9.3± 5.0 7.8± 4.1 0.420
Mean RV pressure
Pre-PMV 8.6± 4.3 8.5± 4.4 9.0± 4.5 0.780
Post-PMV 9.9± 5.4 10.0± 5.7 9.7± 4.4 0.880
Mean PA pressure
Pre-PMV 32.0± 12.7 31.3± 12.8 34.9± 13.5 0.350
Post-PMV 24.7± 8.5 23.2± 7.6 30.0± 10.8 0.010
PCW pressure
Pre-PMV 23.7± 7.8 23.1± 7.7 26.5± 8.1 0.140
Post-PMV 18.3± 7.3 17.3± 6.6 20.8± 8.9 0.130
LA pressure
Pre-PMV 22.8± 7.6 22.6± 7.5 24.3± 7.4 0.450
Post-PMV 16.9± 7.5 16.5± 6.3 19.6± 11.0 0.170
End-diastolic LV pressure
Pre-PMV 13.5± 9.3 13.4± 10.5 14.1± 5.0 0.800
Post-PMV 14.6± 6.7 14.0± 6.8 16.3± 6.2 0.240
Systolic LV pressure
Pre-PMV 133.6± 26.8 134.5± 27.4 132.4± 27.7 0.790
Post-PMV 128.3± 28.4 127.7± 29.4 134.1± 26.8 0.440
CO: cardiac output; LA: left atrial; LV: left ventricular; MVA: mitral valve area; MG: mitral gradient; MR: mitral regurgitation; PA: pul-
monary artery; PCW: pulmonary capillary wedge pressure; PMV: percutaneous mitral valvuloplasty; RA: right atrial; RV: right ventricular.
All pressures and gradients are in mmHg.



































































































tFigure 1 Cumulative incidence of mitral re-intervention after
percutaneous mitral valvuloplasty (PMV).
deaths occurred in the group that underwent post-PMV
mitral re-intervention.
We therefore analyzed the group of patients with
long-term follow-up available who had not proceeded
immediately to surgery due to severe iatrogenic mitral
regurgitation (n=82).
Regarding clinical characteristics, patients who required
mitral re-intervention during follow-up were younger
(43.3±12.8 vs. 51.2±13.8 years, p=0.04) and had higher
pre-PMV MG (14.9±5.1 vs. 11.5±5.0mmHg, p=0.02), post-
PMV MG (6.4±6.8 vs. 2.1±2.2mmHg, p<0.001) and post-PMV
mean pulmonary artery pressure (mPAP) (30.0±10.8 vs.
23.2±7.6mmHg, p=0.01). Using a Cox proportional hazards
model, mPAP was the only predictor of post-PMV mitral re-
intervention (hazard ratio [HR] 5.639 [95% CI 1.246--25.528],
p=0.025) (Table 3). The best immediate post-PMV mPAP cut-
off value for predicting mitral re-intervention was 25mmHg,
with a sensitivity of 81% (95% CI 41--89) and a speci-
ﬁcity of 57% (95% CI 49--75). Patients with immediate
post-PMV mPAP <25mmHg showed signiﬁcantly higher mitral
re-intervention-free survival rates than those with post-
PMV mPAP≥ 25mmHg (94.1% vs. 68.6%), log-rank p=0.01
(Figure 2). Mean PAP≥25mmHg also had independent pre-
dictive value for the occurrence of the composite endpoint
(HR 3.622 [1.070--12.260], p=0.039) (Table 3). Patients
with post-PMV mPAP <25mmHg had signiﬁcantly higher clin-
ical event-free survival rates than those with post-PMV
mPAP≥ 25mmHg (88.2% vs. 60.0%), log-rank p=0.007.
Discussion
PMV is an effective and safe method of relieving MS.
However, sooner or later, a proportion of patients require
re-intervention due to restenosis of the mitral oriﬁce or
increasing severity of MR. We analyzed this group of patients
and performed a comparison with patients who did not
require such intervention and used a clinical endpoint cho-
sen for its relevance to patients, as opposed to a purely




iercutaneous mitral valvuloplasty (PMV) according to immedi-
te post-PMV mean pulmonary artery pressure (mPAP), log-rank
=0.001.
ccur in relatively asymptomatic patients and consequently
as little clinical value.
We deﬁned successful PMV as MVA≥ 1.5 cm2 and
R≤ 2/4. Since MS patients with MVA≥ 1.5 cm2 are gen-
rally considered to have mild stenosis and are relatively
symptomatic, this value was chosen as the threshold for
rocedural success.16 Using this deﬁnition, we observed a
MV procedural success rate of 82.4%. Other studies, using
he same deﬁnition, reported success rates ranging from
0 to 90%.3,17 In all patients, PMV was performed with the
noue balloon technique. The main advantages of this tech-
ique (versus the double-balloon technique) are the absence
f a guidewire in the left ventricle, the self-positioning of
he balloon, and the ability to perform stepwise inﬂations
nder echo guidance to monitor commissural opening.18 MR
emains one of the most important complications of this pro-
edure. In our population, 4.5% of patients (n=4) developed
igniﬁcant MR after PMV, with three requiring mitral surgery.
ifferences in patient populations, selection criteria for sig-
iﬁcant MR, and PMV technique (double-balloon vs. Inoue
alloon technique) may explain the wide range of signiﬁcant
R rates reported in the literature (7.5--15.0%).19--22
It is generally accepted that patients with echo scores
8 have a better outcome with PMV.3 Our study reports a
edian score of 6 (5--7), with eight patients presenting with
score of 8. Previous studies identiﬁed echo score as an
ndependent predictor of surgery.23 However, this was not
he case in our population as no differences were found
etween the groups; this observation is probably related
o the fact that all patients included had an echo score
f ≤8.
In our series mitral re-intervention-free survival rates
ere similar to other published reports, even considering
he fact that in some patients (17.6%) the procedure was
ot successful according to the above deﬁnition.12 Regarding
linical event-free survival, we decided to include decom-
ensated heart failure in our composite clinical endpoint,
n addition to mitral re-intervention and cardiovascular
24 E. Jorge et al.





HR (95% CI) p HR (95% CI) p
Age (years) 0.984 (0.933--1.037) 0.541 0.998 (0.961--1.036) 0.907
Body mass index (kg/m2) 0.836 (0.683--1.023) 0.082 0.996 (0.864--1.148) 0.955
Pre-PMV MG ≥13mmHg 0.994 (0.212--4.665) 0.994 2.648 (0.913--7.681) 0.073
Post-PMV mPAP ≥25mmHg 8.259 (1.378--49.941) 0.021 3.622 (1.070--12.260) 0.039
Post-PMV MG ≥2.5mmHg 3.123 (0.721--13.519) 0.128 0.935 (0.313--2.792) 0.904

















































































eath, as this is a signiﬁcant cardiac event which causes
igniﬁcant burden in terms of quality of life and use of health
esources. Probably due to the fact that most series do not
nclude decompensated heart failure as an endpoint, our
vent-free rates are slightly lower than those reported by
ther groups.12
Within the group that required post-PMV mitral re-
ntervention, four patients repeated PMV, eight underwent
itral valve replacement and seven mitral repair. All those
ndergoing mitral valve replacement had a mechanical
evice implanted. This is probably related to two factors.
irst, given the relatively young age of our study group,
mplanting a mechanical valve could avoid future opera-
ions. Second, a signiﬁcant proportion of these patients were
n atrial ﬁbrillation and on warfarin, so a decision for life-
ong anticoagulation due to a mechanical valve would have
een easier to take. No deaths were observed in the group
ndergoing mitral re-intervention.
The present study found that immediate post-PMV mPAP
as the only independent predictor of the two prede-
ned endpoints, with the best cut-off value for predicting
itral re-intervention being 25mmHg. The most commonly
eported independent predictors of post-PMV clinical events
cardiovascular death, mitral valve surgery and repeat
MV) and restenosis are echo score and post-PMV MVA,
oth related to mitral valve anatomy.2,6,7,12,23 However, our
esults are in agreement with similar studies that also
dentiﬁed mPAP as an independent predictor of event-free
urvival.2,6 Differences in the deﬁnition of endpoints and in
aseline population characteristics may explain the differ-
nt predictors reported in the literature.
In mitral stenosis, pulmonary hypertension (PH) is due
o three components: (1) passive, due to left atrial hyper-
ension; (2) vasoreactive, due to pulmonary arteriolar
onstriction; and (3) due to structural changes in pulmonary
ascular disease.24--26 The ﬁrst two are reversible, the ﬁrst
mmediately after PMV and the second later, within a few
onths of intervention.27 The third factor is permanent and
oes not usually regress.28
In our population, no differences were found in pre-
nd post-PMV MVA between the two groups of patients.
his lack of association between relief of mitral obstruc-
ion and improvement in pulmonary hemodynamics has
een seen in other studies.25,29 Patients who underwent
itral re-intervention had higher post-PMV mPAP. The initial




pmmediate decrease in left atrial pressure and the remain-
er is due to the second and third components described
bove. Indeed, and as reported in other studies, the gain
n MVA is not predictive of a decrease in PA pressure.
espite similar MVA and echo scores, patients who required
itral re-intervention during follow-up had higher mPAP.
hese ﬁndings may suggest that mPAP may be an important
arker of disease severity, probably reﬂecting the chronicity
f the disease, as the duration of stenosis is an impor-
ant factor in the development of reactive PH.30 Although
he vasoreactive component of PH in mitral stenosis may
mprove in the ﬁrst few months after the procedure and
onsequently will have no inﬂuence on long-term outcome
ollowing PMV, the fact remains that patients with higher
PAP immediately after the procedure had a higher inci-
ence of post-PMV re-intervention. This is probably due to a
redominant component of non-reversible vascular remod-
ling in these patients, reﬂecting longer and/or more severe
itral ﬂow restriction. Closer post-PMV follow-up should be
onsidered in these patients.
Although our study represents the largest cohort of PMV
atients with long-term follow-up data reported to date
n Portugal, it has several shortcomings. First, the study
eﬂects a single-center experience and includes a relatively
mall number of patients, all with an echo score under
, reﬂecting the selected nature of the population. Sec-
nd, regular long-term echocardiographic follow-up was not
ossible in a signiﬁcant proportion of patients, so no data
egarding long-term mPAP were available. We used Seller’s
ualitative criteria to assess MR, rather than more accu-
ate quantitative echocardiographic indices, and were thus
nable to account for the post-procedural MR mechanism.
owever, we believe that this is not likely to affect our main
esults and conclusions.
onclusions
n conclusion, in our population, immediate post-PMV mPAP
as the sole predictor of post-PMV mitral re-intervention.
he best immediate mPAP cut-off value for predicting
itral re-intervention was 25mmHg. These ﬁndings may
elp identify patients with more severe disease with a
igher probability of requiring mitral re-intervention. Closer

















2Mean pulmonary arterial pressure after percutaneous mitral
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